Page 2 - Liquidia Technologies News Today

Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIAConfirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C.,...

Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placementAdditional advance of $25.0 million from...

Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placementAdditional advance of $25.0 million from HealthCare Royalty under current financing...

Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placementAdditional advance of $25.0 million from HealthCare Royalty under current financing agreement

MORRISVILLE, N.C., Jan. 02, 2024 -- Liquidia Corporation announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on...

Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalationLiquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C., Dec. 20, 2023

-- Enlivex Therapeutics said it completed enrollment of all 120 patients in a phase 2 trial of Allocetra in patients with sepsis, a life-threatening disease with no therapies approved by the US Food...

Liquidia will pursue final FDA approval for YUTREPIA™ inhalationLiquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C., Dec. 20, 2023 ...

The biotech stock with the BofA's biggest upside already has approval for a drug that treats a rare kidney disease affecting up to 150,000 people in the U.S.

MORRISVILLE, N.C., Dec. 12, 2023 -- Liquidia Corporation announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a public offering price of $7.16...